Search Within

Gabriella D'Andrea-Carlino

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (27)
Groups
  1. Breast Medicine Service (55)
  2. Department of Medicine (55)
  3. Epidemiology and Biostatistics (55)
  4. Solid Tumor Oncology Division (55)
  5. Survivorship Research (55)
  6. Biostatistics Service (48)

More Groups

People
  1. Clifford Hudis (48)
  2. Larry Norton (33)
  3. Diana Lake (32)
  4. Monica Fornier (30)
  5. Sujata Patil (27)
  6. Shanu Modi (25)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2018 (2)
  4. 2017 (2)
  5. 2016 (2)
  6. 2015 (4)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Cancer Research (10)
  3. Clinical Cancer Research (8)
  4. Breast Cancer Research and Treatment (7)
  5. Clinical Breast Cancer (6)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (18)
  2. American Society of Clinical Oncology (15)
  3. Springer (8)
  4. Elsevier Inc. (7)
  5. Oxford University Press (3)
  6. Wiley Blackwell (2)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Journal Article

    Modi, S.; Currie, V. E.; Seidman, A. D.; Bach, A. M.; Panageas, K. S.; Theodoulou, M.; Moasser, M. M.; D'Andrea, G. M.; Lake, D. E.; Choi, J.; more...
    Clinical Breast Cancer (2005)

    Fulltext@MSK | Save
  • Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Journal Article

    Dang, C. T.; Dannenberg, A. J.; Subbaramaiah, K.; Dickler, M. N.; Moasser, M. M.; Seidman, A. D.; D'Andrea, G. M.; Theodoulou, M.; Panageas, K. S.; Norton, L.; more...
    Clinical Cancer Research (2004)

    Fulltext@MSK | Save
  • Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Journal Article

    Dang, C. T.; D'Andrea, G. M.; Moynahan, M. E.; Dickler, M. N.; Seidman, A. D.; Fornier, M.; Robson, M. E.; Theodoulou, M.; Lake, D.; Currie, V. E.; more...
    Clinical Cancer Research (2004)

    Fulltext@MSK | Save
  • Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    Journal Article

    Seidman, A. D.; Fornier, M. N.; Esteva, F. J.; Tan, L.; Kaptain, S.; Bach, A.; Panageas, K. S.; Arroyo, C.; Valero, V.; Currie, V.; more...
    Journal of Clinical Oncology (2001)

    Fulltext@MSK | Save
  • Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Theodoulou, M.; Moynahan, M. E.; Currie, V.; Moasser, M.; Sklarin, N.; Gilewski, T.; D'Andrea, G.; Salvaggio, R.; more...
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save